Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Krebs Biochemicals & Industries has informed that the second term of appointment of Satish Khemchand Khivsara (DIN: 07244464) as an Independent Director of the Company is ending on 31st March 2025. Accordingly, he ceases to be an Independent Director/ Director of the Company with effect from 1st April 2025. The Company has immensely benefited from his knowledge and guidance as well as advices given by him during his tenure as an independent director. The Board places on record its sincere appreciation for the services rendered by him during his tenure as an Independent Director of the Company. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 is attached as Annexure-1.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1666.00 |
| Dr. Reddys Lab | 1229.50 |
| Cipla | 1228.15 |
| Zydus Lifesciences | 934.00 |
| Lupin | 2329.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: